鍾南山:兩款覆蓋XBB變異株疫苗已初步獲批 6月底或是今年疫情高峰
中國科學院院士鍾南山今日(22日)在一個論壇稱,能覆蓋新冠XBB變異株的疫苗有2個已經初步獲批准,很快能面世;另還有三、四種很快能被批准。他表示,研究更加有效的疫苗,中國是能走在國際前列。
此外,鍾南山還說,根據多方面材料判斷,4月底、5月初有一個新冠病毒感染的小高峰,這是預料到的。
基於seirs 模型的預測顯示,2023年新冠第二波疫情高峰料發生在6月底,每周約6,500萬人受感染。鍾氏稱,一個Omicron感染者可傳染30多人,內地的防控戰略已經從過去的預防感染調整為現在的預防重症,因為感染是很難預防的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.